JP2023516653A - 予測可能な液体と液体の相分離を有するタンパク質 - Google Patents

予測可能な液体と液体の相分離を有するタンパク質 Download PDF

Info

Publication number
JP2023516653A
JP2023516653A JP2022552436A JP2022552436A JP2023516653A JP 2023516653 A JP2023516653 A JP 2023516653A JP 2022552436 A JP2022552436 A JP 2022552436A JP 2022552436 A JP2022552436 A JP 2022552436A JP 2023516653 A JP2023516653 A JP 2023516653A
Authority
JP
Japan
Prior art keywords
seq
ratio
polypeptide
protein
idp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516653A5 (cg-RX-API-DMAC10.html
Inventor
マイケル ズリッキー
アシュトッシュ チルコティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2023516653A publication Critical patent/JP2023516653A/ja
Publication of JP2023516653A5 publication Critical patent/JP2023516653A5/ja
Priority to JP2026022998A priority Critical patent/JP2026091842A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022552436A 2020-03-04 2021-03-03 予測可能な液体と液体の相分離を有するタンパク質 Pending JP2023516653A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026022998A JP2026091842A (ja) 2020-03-04 2026-02-16 予測可能な液体と液体の相分離を有するタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985179P 2020-03-04 2020-03-04
US62/985,179 2020-03-04
PCT/US2021/020591 WO2021178483A2 (en) 2020-03-04 2021-03-03 Proteins with predictable liquid-liquid phase separation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026022998A Division JP2026091842A (ja) 2020-03-04 2026-02-16 予測可能な液体と液体の相分離を有するタンパク質

Publications (2)

Publication Number Publication Date
JP2023516653A true JP2023516653A (ja) 2023-04-20
JP2023516653A5 JP2023516653A5 (cg-RX-API-DMAC10.html) 2024-03-12

Family

ID=77613702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552436A Pending JP2023516653A (ja) 2020-03-04 2021-03-03 予測可能な液体と液体の相分離を有するタンパク質
JP2026022998A Pending JP2026091842A (ja) 2020-03-04 2026-02-16 予測可能な液体と液体の相分離を有するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026022998A Pending JP2026091842A (ja) 2020-03-04 2026-02-16 予測可能な液体と液体の相分離を有するタンパク質

Country Status (5)

Country Link
US (1) US20230086188A1 (cg-RX-API-DMAC10.html)
EP (1) EP4087856A4 (cg-RX-API-DMAC10.html)
JP (2) JP2023516653A (cg-RX-API-DMAC10.html)
AU (1) AU2021231786A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021178483A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12269847B2 (en) 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
US12692483B2 (en) 2020-02-19 2026-07-28 Donaldson Company, Inc. Protein-based purification matrices and methods of using the same
EP4107268A4 (en) 2020-02-19 2024-03-27 Donaldson Company, Inc. PURIFICATION MATRICES COMPRISING VAA-BINDING POLYPEPTIDES AND METHODS OF USE THEREOF
US20250115886A1 (en) * 2021-08-02 2025-04-10 The Trustees Of The University Of Pennsylvania Designer membraneless organelles sequester native factors for control of cell behavior
CN114712487B (zh) * 2022-05-17 2024-09-03 清华大学 无序蛋白序列在抗生物污染中的用途
WO2025060384A1 (zh) * 2023-09-22 2025-03-27 小熊猫有限公司 一种基于合成细胞器的目标产物回收方法、dna构建体和表达系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121709A1 (en) * 2010-09-24 2012-05-17 Ashutosh Chilkoti Phase transition biopolymers and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
JPWO2017171001A1 (ja) * 2016-03-31 2019-02-14 味の素株式会社 フィブロイン様タンパク質改変体および細胞培養方法
CN110914386A (zh) * 2017-06-12 2020-03-24 杜克大学 用于生产生物分子的组合物、系统和方法
US12269847B2 (en) * 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
GB201815285D0 (en) * 2018-09-19 2018-10-31 Univ London Queen Mary Self-assembly graphene oxide-protein matrix

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121709A1 (en) * 2010-09-24 2012-05-17 Ashutosh Chilkoti Phase transition biopolymers and methods of use

Also Published As

Publication number Publication date
US20230086188A1 (en) 2023-03-23
WO2021178483A3 (en) 2021-11-18
EP4087856A4 (en) 2024-03-06
WO2021178483A2 (en) 2021-09-10
AU2021231786A1 (en) 2022-09-08
EP4087856A2 (en) 2022-11-16
JP2026091842A (ja) 2026-06-04

Similar Documents

Publication Publication Date Title
US20230086188A1 (en) Proteins with predictable liquid-liquid phase separation
Dzuricky et al. De novo engineering of intracellular condensates using artificial disordered proteins
King et al. Phase separation of TPX2 enhances and spatially coordinates microtubule nucleation
Zeno et al. Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing
Babl et al. CTP-controlled liquid–liquid phase separation of ParB
Pazos et al. Z-ring membrane anchors associate with cell wall synthases to initiate bacterial cell division
Tubio et al. Relationship between the protein surface hydrophobicity and its partitioning behaviour in aqueous two-phase systems of polyethyleneglycol–dextran
US20180258157A1 (en) Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
CN108463244B (zh) 用于递送的基因编码的固有无序隐形聚合物及其使用方法
JP2008292371A (ja) 蛍光相関分光による複数成分相互作用の分析方法及び相互作用制御化合物のスクリーニング方法
US20110059549A1 (en) Methods and systems for producing nanolipoprotein particles
JP7795205B2 (ja) タンパク質ナノ粒子の設計および適用
US12084480B2 (en) Unstructured non-repetitive polypeptides having lcst behavior
Yamniuk et al. Application of a kosmotrope‐based solubility assay to multiple protein therapeutic classes indicates broad use as a high‐throughput screen for protein therapeutic aggregation propensity
JP7598843B2 (ja) 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
Sharma et al. Plasma membrane compartmentalization of D2 dopamine receptors
Zoonens et al. Amphipols: a general introduction and some protocols
Jedlitzke et al. A light‐activatable photocaged variant of the ultra‐high affinity ALFA‐tag nanobody
Davis et al. Protein-protein interactions in the assembly of Shigella flexneri invasion plasmid antigens IpaB and IpaC into protein complexes
Jacobsen et al. Amine landscaping to maximize protein-dye fluorescence and ultrastable protein-ligand interaction
Pham et al. The role of the size of affinity ligands in the detection and characterization of extracellular vesicles
Zoghbi et al. Membrane protein reconstitution in nanodiscs for luminescence spectroscopy studies
US20220281931A1 (en) Chemically inducible polypeptide polymerization
Beevers et al. Sequence-dependent oligomerization of the Neu transmembrane domain suggests inhibition of “conformational switching” by an oncogenic mutant
Herlax et al. Role of lipopolysaccharide on the structure and function of α-hemolysin from Escherichia coli

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260216